Flaxseed Lignan Complex Administration in Older Human Type 2 Diabetics Manages Central Obesity and Prothrombosis—An Invitation to Further Investigation into Polypharmacy Reduction

D E Barre,J Hobson,K A Mizier-Barre,A Rudiuk,O Griscti,D Muthuthevar,E Stelmach

doi:10.1155/2012/585170

Abstract

Aim. Animal and human study evidence supports the hypothesis that flaxseed lignan complex (FLC) at a dose of 600 mg secoisolariciresinol diglucoside (SDG)/day for three months would combat hyperglycaemia, dyslipidemia, blood pressure, central obesity, prothrombotic state, inflammation, and low density lipoprotein (LDL) oxidation. Methods. Sixteen type 2 diabetic patients completed this double-blind, randomised crossover placebo-controlled study. A univariate repeated measures analysis of covariance (significance P < 0.05) was followed by a mixed linear model effects analysis corrected for multiple comparisons (MCC). Results. Prior to MCC, FLC caused decreased fasting plasma glucose, A1c, inflammation (c-reactive protein (CRP) and interleukin-6 (IL-6)), and increased bleeding time. After correction for multiple comparisons, FLC induced a statistically significant increase in bleeding time and smaller waist circumference gain. No treatment effect occurred in the other variables before or after adjustment. Conclusions. It is concluded that FLC significantly increased bleeding time thus reducing the prothrombotic state, reduced central obesity gain as measured by waist circumference, and did not affect significantly the other dependent variables measured after adjustment for multiple comparisons. These findings, not yet published in human type 2 diabetes, suggest that this FLC dose over at least three months, may, subject to further investigation, reduce polypharmacy.

Highlights

Type 2 diabetics face numerous clinical features
Pan et al (2009 [34]) administering flaxseed lignan complex (FLC) (360 mg secoisolariciresinol diglucoside (SDG)/day) to type 2 diabetics for 12 weeks in a study of similar design to the current study found that CRP level rises were reduced relative to placebo and there were no treatment changes in IL-6 or TNF-α relative to placebo
It is concluded that this FLC given at a dose of 600 mg SDG/day for three months combats in a statistically significant fashion, in this study population, waist circumference gain, and the prothrombotic state and potentially the risk of myocardial infarction and stroke

Summary

Introduction

Type 2 diabetics face numerous clinical features Chief among these are seven: central obesity, hyperglycaemia, dyslipidemia, hypertension, inflammation, LDL oxidation, and the prothombotic state. The sequelae of these features, atherosclerotic-driven myocardial infarction and stroke [1, 2], are the major causes of disability and death in type 2 diabetes patients [3]. Type 2 diabetes is diagnosed when there is a fasting plasma glucose of ≥7.0 mmol/L or, as the result of a 2 hour after oral glucose tolerance test (or at any random time of the day), a blood glucose level of ≥11.1 mmol/L.

Objectives

Methods

Results

Conclusion